Incyte reported $38.27M in Debt for its fiscal quarter ending in June of 2026.





Debt Change Date
Acadia Pharmaceuticals USD 73.85M 23.06M Jun/2026
Agenus USD 35.54M 2.34M Mar/2025
Agios Pharmaceuticals USD 31.17M 4.57M Jun/2026
Alnylam Pharmaceuticals USD 2.48B 1.21B Sep/2026
Amgen USD 57.3B 19M Jun/2026
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Biogen USD 7.69B 398.3M Sep/2026
BioMarin Pharmaceutical USD 4.19B 11.99M Sep/2026
Bristol-Myers Squibb USD 42.88B 2.18B Sep/2026
Eli Lilly USD 54.91B 11.54B Jun/2026
Exelixis USD 162.2M 3.73M Sep/2026
Gilead Sciences USD 26.25B 4.07B Jun/2026
Incyte USD 38.27M 1.16M Jun/2026
Ionis Pharmaceuticals USD 1.77B 141M Sep/2026
MacroGenics USD 35.09M 1.42M Jun/2026
Merck USD 53.91B 4.79B Jun/2026
Moderna USD 1.29B 11M Jun/2026
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 392.3M 9.5M Sep/2026
Novartis USD 49.01B 2.02B Jun/2026
Novartis USD 48.31B 1.31B Sep/2026
Pfizer USD 62.67B 523M Sep/2026
PTC Therapeutics USD 2.84B 2.15B Sep/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Sarepta Therapeutics USD 857.36M 188.48M Sep/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vertex Pharmaceuticals USD 6.48B 4.5B Sep/2026